Maurizio Battaglia Parodi, Umberto De Benedetto, Karl Anders Knutsson, Fabrizio Scotti, Aloisa Librando, Francesco Bandello, Pierluigi Iacono
Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milano, Italy.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2012 AprTo describe a case of juxtafoveal choroidal neovascularization (CNV) occurring in a patient affected by retinitis pigmentosa (RP), treated with intravitreal bevacizumab over a 12-month follow-up. A 66 year-old woman referred to our center for visual acuity deterioration was diagnosed as having classic juxtafoveal CNV associated with RP. The patient was treated with intravitreal bevacizumab, and was regularly monitored every month. At the end of the 12-month follow-up, best corrected visual acuity changed from 20/200 to 20/100 in the affected eye. Five intravitreal bevacizumab injections were required to obtain the stabilization of the CNV. Intravitreal bevacizumab is effective in producing juxtafoveal CNV stabilization and visual acuity improvement in a patient affected by RP, over a 12-month follow-up. Future studies are required to ascertain the best therapeutic approach for CNV complicating RP.
Maurizio Battaglia Parodi, Umberto De Benedetto, Karl Anders Knutsson, Fabrizio Scotti, Aloisa Librando, Francesco Bandello, Pierluigi Iacono. Juxtafoveal choroidal neovascularization associated with retinitis pigmentosa treated with intravitreal bevacizumab. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2012 Apr;28(2):202-4
PMID: 22149640
View Full Text